Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

BARCELONA, Spain, Nov. 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that its investigational medicine canagliflozin substantially lowered blood glucose levels compared to placebo when used as add-on therapy in patients with type 2 diabetes who are inadequately controlled with the antihyperglycemic medications metformin and pioglitazone. These results were presented at the 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy). 

The data presented are the latest Phase 3 results for canagliflozin, which is being evaluated across a spectrum of patients with type 2 diabetes. Results from the study (known as DIA3012) showed that canagliflozin, dosed once daily at 100 mg or 300 mg in addition to metformin and pioglitazone, had statistically greater A1C reductions at 26 weeks relative to placebo (change from baseline, -0.89% and -1.03%, vs. -0.26%, respectively, p<0.001). The overall incidence of adverse events (AEs) was generally similar across all treatment arms.

"Given the global diabetes epidemic and the significant burden faced by patients who suffer from uncontrolled diabetes, it is critical that we evaluate new therapies in combination with existing antihyperglycemic therapies," said Dr. Thomas Forst, lead investigator on the study from the University of Mainz in Mainz, Germany. "The efficacy and safety profile for canagliflozin in this trial is encouraging. This data combined with other results seen to date, show that canagliflozin may provide added benefit in managing important diabetes parameters when used alone or in addition to existing diabetes treatments."

In secondary efficacy endpoint measures of the study, both the canagliflozin 100 mg and 300 mg dose groups provided reductions in body weight compared to placebo (-2.8% and -3.8% vs. -0.1%, respectively, p<0.001) and reductions in systolic blood pressure (-5.3 mmHg, p<0.01 and -4
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA Pharma ... its common shares have been approved for listing and trading ... ESSA will begin trading on NASDAQ on July ... TSX Venture Exchange under the symbol "EPI". As ... the NASDAQ, each of the Company,s outstanding special warrants issued ...
(Date:7/2/2015)... , July 2, 2015  Fort Lauderdale-based ... pleased to announce that its Consumer Group completed ... to Kerry Group plc (ISE: KRZ) ("Kerry"), one ... and nutrition systems, as well as functional ingredients ... pharmaceutical markets. Farlie Turner served as the exclusive ...
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
... Nov. 11, 2010 Applied Precision, a leader in life ... four of its revolutionary DeltaVisio n OMX® ... weeks. The Delta V ision ... than doubles the optical resolution of the traditional light microscope ...
... Reata Pharmaceuticals today announced that the company will present ... clinical trial of bardoxolone methyl in patients with ... The data will be presented in a late-breaking oral presentation ... Conference to be held November 16-21, 2010, in Denver, ...
Cached Medicine Technology:Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks 2Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease 2Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease 3
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... Md. (PRWEB) , ... July 02, 2015 , ... Six ... in his solo cross-country walk to raise awareness and money for the Pulmonary ... expects to arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... (PRWEB) , ... July 02, ... ... wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on the ... development. Complete report on negative pressure wound therapy (NPWT) with 22 market ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... announced today that it has reached an agreement to acquire eRubbermaid.com, an ... largest distributor of Rubbermaid Commercial Products on the web today. ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:CleanItSupply.com Acquires eRubbermaid.com 2
... modified strain, has led to the death of a 27-week-old ... mature babies are undergoing treatment. ,The babies are ... they were found to be carriers of Panton-Valentine Leukocidin (PVL) ... ,Hospital authorities have confirmed that the baby died due to ...
... PLoS Medicine, doctors report on the case of a ... accident and emergency department //with double vision, slurred speech, ... out to be wound botulism. ,Wound botulism is ... the bacterium Clostridium botulinum contaminate a wound, germinate, and ...
... Kerala promises heavy investment opportunities for Non-Resident Keralites (NRK), ... the// long term. ,Kerala Tourism Department ... March 23 – 27 for showcasing the opportunities in ... be a congregation of major hospitals, health insurance companies, ...
... and Drug Administration (FDA) will release its approval for consumption ... ,Two federal scientists, Larisa Rudenko and John C. ... and milk of cloned animals and their offspring. “On no ... animals from normal animals,” they say. ,A formal ...
... suffer at the Patna Medical College and Hospital (PMCH) ... strike demanding security, despite assurances from the Bihar government. ... an alleged attack on some of them by attendants ... Rai gave an assurance to fulfil their demands, Vinod ...
... reduced the use of illicit drugs, but have got ... opine. , ,The MTF survey has been the ... since 1975. The most recent survey, collating information from ... classes eighth, 10th and 12th grades has revealed that ...
Cached Medicine News:
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
... Patients who need punctal occlusion ... eye relief. They also want ... as comfortable and as unobtrusive ... Alcon punctal plugs are growing ...
10 (mm) smooth platform; Serrated handle in stainless steel....
... Only Heartlab delivers the performance ... cardiovascular information management systems. As ... and services set the benchmark. ... functionality, high-speed performance and technological ...
Medicine Products: